Oncternal Therapeutics (NASDAQ:ONCT) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a research note issued on Friday. The firm set a “hold” rating on the stock.

Separately, HC Wainwright decreased their price objective on shares of Oncternal Therapeutics from $30.00 to $28.00 and set a “buy” rating for the company in a research note on Monday, April 15th.

Oncternal Therapeutics Stock Performance

Shares of NASDAQ:ONCT opened at $8.75 on Friday. The firm has a market cap of $25.89 million, a price-to-earnings ratio of -0.65 and a beta of 1.28. The firm has a fifty day moving average price of $8.79 and a 200 day moving average price of $8.31. Oncternal Therapeutics has a fifty-two week low of $5.57 and a fifty-two week high of $13.14.

Oncternal Therapeutics (NASDAQ:ONCT) last issued its quarterly earnings results on Thursday, March 7th. The company reported ($3.11) EPS for the quarter, missing the consensus estimate of ($3.09) by ($0.02). The firm had revenue of $0.30 million for the quarter, compared to the consensus estimate of $0.17 million. Oncternal Therapeutics had a negative net margin of 5,029.17% and a negative return on equity of 95.87%. During the same quarter in the previous year, the company posted ($4.00) earnings per share. As a group, research analysts predict that Oncternal Therapeutics will post -10.67 earnings per share for the current year.

Insider Buying and Selling at Oncternal Therapeutics

In related news, Director Robert James Wills purchased 3,086 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was purchased at an average price of $8.96 per share, with a total value of $27,650.56. Following the completion of the transaction, the director now owns 10,000 shares of the company’s stock, valued at approximately $89,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders have acquired 10,714 shares of company stock valued at $92,736 over the last quarter. Corporate insiders own 8.00% of the company’s stock.

Institutional Trading of Oncternal Therapeutics

An institutional investor recently raised its position in Oncternal Therapeutics stock. Richmond Brothers Inc. grew its stake in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT) by 69.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 494,042 shares of the company’s stock after purchasing an additional 203,010 shares during the quarter. Oncternal Therapeutics makes up 0.3% of Richmond Brothers Inc.’s portfolio, making the stock its 22nd largest holding. Richmond Brothers Inc. owned about 0.84% of Oncternal Therapeutics worth $148,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 16.05% of the company’s stock.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.